

# Mohammed Lamorde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8243282/publications.pdf>

Version: 2024-02-01

75  
papers

1,371  
citations

361296

20  
h-index

414303

32  
g-index

84  
all docs

84  
docs citations

84  
times ranked

1958  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Willingness to pay for an mHealth anti-retroviral therapy adherence and information tool: Transitioning to sustainability, Call for life randomised study experience in Uganda. BMC Medical Informatics and Decision Making, 2022, 22, 52.                            | 1.5  | 2         |
| 2  | Stable warfarin dose prediction in sub-Saharan African patients: A machine learning approach and external validation of a clinical dose initiation algorithm. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 20-29.   | 1.3  | 10        |
| 3  | Developing and Validating a Clinical Warfarin Dose Initiation Model for Black African Patients in South Africa and Uganda. Clinical Pharmacology and Therapeutics, 2021, 109, 1564-1574.  | 2.3  | 8         |
| 4  | An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial. JMIR MHealth and UHealth, 2021, 9, e22229.  | 1.8  | 23        |
| 5  | T-Cell Homeostatic Imbalance in Placentas From Women With Human Immunodeficiency Virus in the Absence of Vertical Transmission. Journal of Infectious Diseases, 2021, 224, S670-S682.   | 1.9  | 6         |
| 6  | Implementation of the World Health Organization Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study Using National Surveillance Data. JMIR Public Health and Surveillance, 2021, 7, e29954.                                 | 1.2  | 12        |
| 7  | Blood Culture Testing Outcomes among Non-Malarial Febrile Children at Antimicrobial Resistance Surveillance Sites in Uganda, 2017-2018. Tropical Medicine and Infectious Disease, 2021, 6, 71.  | 0.9  | 2         |
| 8  | Acceptability of a Mobile Phone Support Tool (Call for Life Uganda) for Promoting Adherence to Antiretroviral Therapy Among Young Adults in a Randomized Controlled Trial: Exploratory Qualitative Study. JMIR MHealth and UHealth, 2021, 9, e17418.                  | 1.8  | 17        |
| 9  | Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes in Uganda (CFL-TB): a protocol for a randomized controlled trial. Trials, 2021, 22, 391.  | 0.7  | 29        |
| 10 | Safer primary healthcare facilities are needed to protect healthcare workers and maintain essential services: lessons learned from a multicountry COVID-19 emergency response initiative. BMJ Global Health, 2021, 6, e005833.  | 2.0  | 21        |
| 11 | Optimizing antimicrobial use: challenges, advances and opportunities. Nature Reviews Microbiology, 2021, 19, 747-758.   | 13.6 | 51        |
| 12 | In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV Medicine, 2021, 22, 898-906.   | 1.0  | 1         |
| 13 | Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DOLPHIN-1. Clinical Infectious Diseases, 2021, 73, e1200-e1207.  | 2.9  | 11        |
| 14 | Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in Kampala, Uganda. Sexually Transmitted Infections, 2021, 97, 312-316.  | 0.8  | 15        |
| 15 | Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infectious Diseases, 2021, 21, 1154.  | 1.3  | 10        |
| 16 | An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Trials, 2021, 22, 831. | 0.7  | 2         |
| 17 | Implementing routine physical function screening among elderly HIV-positive patients in Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1467-1470.   | 0.6  | 3         |
| 18 | The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women. Drug Safety, 2020, 43, 1133-1140.   | 1.4  | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777. | 1.3 | 69        |
| 20 | Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda. <i>Health Security</i> , 2020, 18, 114-124.   | 0.9 | 4         |
| 21 | Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e332-e339.   | 2.1 | 75        |
| 22 | Dolutegravir-associated hyperglycaemia in patients with HIV. <i>Lancet HIV</i> , 2020, 7, e461-e462.   | 2.1 | 58        |
| 23 | Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 263-272.  | 1.9 | 3         |
| 24 | Pharmacokinetics, Safety/tolerability, and Efficacy of high-dose Rifampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). <i>Trials</i> , 2020, 21, 181.   | 0.7 | 14        |
| 25 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <i>PLoS ONE</i> , 2020, 15, e0227458.   | 1.1 | 25        |
| 26 | Antimicrobial Resistance of Neisseria Gonorrhoeae in a Newly Implemented Surveillance Program in Uganda: Surveillance Report. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e17009.  | 1.2 | 14        |
| 27 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.   |     | 0         |
| 28 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.   |     | 0         |
| 29 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.   |     | 0         |
| 30 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.   |     | 0         |
| 31 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.   |     | 0         |
| 32 | A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.   |     | 0         |
| 33 | High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 135-138.  | 1.3 | 7         |
| 34 | Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3003-3010.  | 1.3 | 13        |
| 35 | Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). <i>PLoS Medicine</i> , 2019, 16, e1002895.  | 3.9 | 58        |
| 36 | Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .  | 1.4 | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. <i>BMC Infectious Diseases</i> , 2019, 19, 280. | 1.3 | 4         |
| 38 | Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .  | 1.4 | 11        |
| 39 | A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz035.  | 0.4 | 5         |
| 40 | Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. <i>Oxford Medical Case Reports</i> , 2019, 2019, omy132.  | 0.2 | 4         |
| 41 | The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 450-457.   | 2.3 | 13        |
| 42 | The Joint Mobile Emerging Disease Clinical Capability (JMEDI) laboratory approach: Capabilities for high-consequence pathogen clinical research. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007787.  | 1.3 | 10        |
| 43 | Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. <i>AIDS Research and Therapy</i> , 2019, 16, 39.  | 0.7 | 5         |
| 44 | Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .  | 1.4 | 16        |
| 45 | Evaluation of the Management of Patients with Detectable Viral Load after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in Uganda. <i>AIDS Research and Treatment</i> , 2019, 2019, 1-5.   | 0.3 | 3         |
| 46 | Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.   | 2.9 | 34        |
| 47 | Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1004-1012.                             | 1.3 | 15        |
| 48 | Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1013-1019.  | 1.3 | 30        |
| 49 | The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. <i>Tuberculosis</i> , 2018, 108, 77-82.   | 0.8 | 14        |
| 50 | Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. <i>Wellcome Open Research</i> , 2018, 3, 111.   | 0.9 | 0         |
| 51 | A Cross-Cutting Approach to Surveillance and Laboratory Capacity as a Platform to Improve Health Security in Uganda. <i>Health Security</i> , 2018, 16, S-76-S-86.  | 0.9 | 21        |
| 52 | Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. <i>Bioanalysis</i> , 2018, 10, 1933-1945.  | 0.6 | 3         |
| 53 | Estimating the cost and cost-effectiveness for obstetric fistula repair in hospitals in Uganda: a low income country. <i>Health Policy and Planning</i> , 2018, 33, 999-1008.   | 1.0 | 13        |
| 54 | Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda. <i>Emerging Infectious Diseases</i> , 2018, 24, 174-175.  | 2.0 | 35        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting. <i>Hepatology, Medicine and Policy</i> , 2018, 3, 3.   | 1.7 | 1         |
| 56 | Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1060, 300-307. | 1.2 | 23        |
| 57 | Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. <i>BMJ Open</i> , 2017, 7, e014679.   | 0.8 | 9         |
| 58 | Antimicrobial Resistance of Sterile Site Infections in Sub-Saharan Africa: A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx209.  | 0.4 | 14        |
| 59 | Cost-effectiveness of expanding childhood routine immunization against <i>Neisseria meningitidis</i> serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. <i>PLoS ONE</i> , 2017, 12, e0188595.  | 1.1 | 7         |
| 60 | Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV. <i>Drug Safety</i> , 2016, 39, 1053-1072.  | 1.4 | 41        |
| 61 | Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. <i>BMC Health Services Research</i> , 2016, 16, 304.   | 0.9 | 49        |
| 62 | Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. <i>Clinical Infectious Diseases</i> , 2016, 62, 675-682.  | 2.9 | 75        |
| 63 | Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004568.   | 1.3 | 34        |
| 64 | Antenatal Syphilis Screening Using Point-Of-Care Testing in Low- and Middle-Income Countries in Asia and Latin America: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2015, 10, e0127379.  | 1.1 | 20        |
| 65 | Cost-effectiveness of Antivenoms for Snakebite Envenoming in Nigeria. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3381.   | 1.3 | 29        |
| 66 | Efavirenz-but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant. <i>Journal of the International AIDS Society</i> , 2014, 17, 19484.   | 1.2 | 23        |
| 67 | Antiretroviral drugs for prevention of mother-to-child transmission. <i>Aids</i> , 2014, 28, 2551-2563.   | 1.0 | 4         |
| 68 | Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique. <i>BMC Infectious Diseases</i> , 2014, 14, 473.  | 1.3 | 10        |
| 69 | Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. <i>Aids</i> , 2013, 27, 961-965.   | 1.0 | 23        |
| 70 | Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-6.  | 0.3 | 25        |
| 71 | Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 295-298.  | 0.9 | 12        |
| 72 | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 180-183.  | 1.3 | 21        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 345-350. | 0.9 | 23        |
| 74 | Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda. <i>Journal of Ethnopharmacology</i> , 2010, 130, 43-53.                                    | 2.0 | 121       |
| 75 | Antiretroviral therapy in developing countries: pharmacologic considerations. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 252-257.   | 1.5 | 1         |